Last update 08 May 2025

IL15R x CD70

Basic Info

Related Targets
IL15RCD70

Related

1
Drugs associated with IL15R x CD70
CAR.70/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center)
Target
CD70 x IL15R
Mechanism
CD70 inhibitors [+1]
Active Org.
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Originator Org.
The University of Texas MD Anderson Cancer CenterThe University of Texas MD Anderson Cancer Center
Active Indication
Myeloid Tumor [+10]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
3
Clinical Trials associated with IL15R x CD70
NCT06930651
/ Not yet recruitingPhase 1/2IIT
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
100 Clinical Results associated with IL15R x CD70
Login to view more data
100 Translational Medicine associated with IL15R x CD70
Login to view more data
0 Patents (Medical) associated with IL15R x CD70
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free